NASDAQ · CLBT

Cellebrite DI news

$10.93−1.26%
Close Sep 29, 2026 · split-adjusted
Articles · 30 days3English, de-duplicated
Positive267% of coverage
Neutral133%
Negative00% of coverage

About Cellebrite DI

Cellebrite's 2026 Outlook: Subscription Pivot Weighs on the Stock Today, Helps Lead a Future Rebound
The Motley FoolSep 29, 1:30 PM ET▲ Positive

Despite near-term headwinds from subscription pivot and CEO transition, the company demonstrates strong fundamentals: 21% ARR growth, 80%+ gross margins, 16% net profit margin, market leadership with 7,000 customers including government agencies, and FedRAMP authorization. The analyst predicts a five-year rebound outperforming the S&P 500, citing AI growth potential and customer stickiness, though execution risks and high valuation (47.58 P/E) require monitoring.

Cellebrite Files its 2025 Annual Report on Form 20-F
BenzingaMar 4, 8:30 AM ETNeutral

The article is a routine regulatory announcement regarding the filing of the annual report. There is no new business information, financial results, or strategic developments disclosed that would indicate positive or negative sentiment. It is a standard procedural disclosure required by securities regulations.

Also mentions CLBT

Articles that tag CLBT but are mainly about other companies.

3 Growth Stocks Worth $5,000 of Your Money -- Even in This Market
The Motley FoolJun 5, 8:20 AM ET▲ Positive

21% annual recurring revenue growth, 32% free cash flow margin, 83.86% gross margin, successful transition to subscription model, strong government contracts, and new Genesis AI product expected to drive future growth.

Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology